H ereditary hemorrhagic telangiectasia (HHT) is a rare, autosomal dominant disorder, clinically diagnosed according to the presence of at least 3 of the 4 following Curaçao criteria: epistaxis, mucocutaneous telangiectasia (TA), visceral arteriovenous malformations (AVM), and familial disease history. 1 AVM, which can theoretically occur in every organ, may lead to life-threatening complications, such as high-output cardiac failure and/or ischemic organ dysfunction. [2] [3] [4] [5] [6] [7] [8] [9] Hepatic vascular malformations have been described in up to 73% of patients. 10 Fortunately, most HHT patients are asymptomatic and less than 5% to 15% of cases are referred with symptoms. According to shunt type and size, Garcia-Tsao has classified patients into 3 groups presenting with cardiac failure, biliary disease, or portal hypertension 2,5,10 -12 The treatment of the disease is still far from standardized. 2, 3, 5, 11, 13, 14 Successful liver transplantation (LT) has been reported in cases of liver failure, extended biliary necrosis, and cardiac failure, all related to intrahepatic AV shunts. [7] [8] [9] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] This analysis aims at a better definition of the value of LT in the current management of HHT with liver involvement, based on a patient cohort of 40 patients reported to the European Liver Transplant Registry (ELTR).
PATIENTS AND METHODS
A questionnaire, including 162 items, was sent to the 14 centers where 40 patients were transplanted for HHT during the period 1985 to 2003. The first part of the questionnaire related to the pretransplant period, including recipient data, biochemistry, clinical and radiologic presentation, diseaserelated complications and concomitant manifestations, alternative treatments, histologic examination, and quality of life (using Karnofsky score and WHO status). The second part focused on the peritransplant period, including donor data, surgical aspects of transplant procedure, transfusion requirements, ischemia times, length of hospitalization, immunosuppression, and histologic examination of the native liver. The third part related to outcome, complications, incidence of rejection, biochemical and histologic follow-up, current immunosuppression, and quality of life after transplantation.
Four questionnaires lacked 21 to 30 items and 3 more than 30 items. Lack of information was mainly due to the unavailability of several items related to the incorrect pretransplant diagnosis and to the insufficient knowledge of this disease at the beginning of the studied time period.
Follow-up was complete for all patients with a mean of 69 months (range, 0 -230 months; median, 70 months). Data are expressed as percentage, mean values, range, and median. Actuarial patient and graft survival rates were calculated according to Kaplan-Meier.
RESULTS
Thirty-five females and 5 males (all white) patients underwent LT for HHT. Incidence of LT over the studied period is as follows: 3 patients from 1995 to 1990, 5 patients from1991 to 1995, 19 patients from 1996 to 2000, and 13 patients from 2001 to 2003. Twenty (54%) of 37 documented patients had a familial HHT history. Mean ages at diagnosis and at moment of LT were 42 years (range, 20 -67 years) and 48 years (range, 27-71 years). Ten (28, 6%) females were postmenopausal (defined as age over 55 years).
HHT was correctly diagnosed before LT in 31 (78%) patients. In the remaining 9 patients, initial diagnosis was cryptogenic cirrhosis (2 patients), primary sclerosing cholangitis (1 patient), secondary biliary cirrhosis (1 patient), unspecified metabolic disease (1 patient), diffuse biliary necrosis with liver abscess (2 patients), peliosis (1 patient), and multifocal hemangioma (1 patient). The final diagnosis of HHT was made by pathologic examination of the hepatectomy specimen. Eight pretransplant liver biopsies showed aspecific vascular anomalies and fibrosis (1 patient), peliosis (1 patient), peliosis and aspecific mesenchymal reaction (1 patient), and hemangioma (1 patient); 4 biopsies were inconclusive. Tables 1 and 2 show the clinical and biochemical presentation of HHT patient population. Nose bleeds (69%), abdominal pain and discomfort (54%), weakness (44%), and nausea, intestinal angina, and pruritus (23% each) were the most frequent symptoms. Telangiectasia (67%), anemia (54%), dyspnea (54%), hepatosplenomegaly (51%), weight loss (46%), jaundice (38%), ascites (38%), febrile episodes (33%), peripheral edema (26%), and hemangioma (8%) were the most frequent signs. Cholestasis (90%), jaundice (71%), and anemia (65%) were the most frequent biochemical abnormalities.
According to the classification of Garcia-Tsao, 11 indications for LT were high-output right cardiac failure (14 patients), diffuse and pronounced biliary necrosis causing hepatic failure (12 patients), severe portal hypertension (5 patients), cardiac failure and biliary necrosis (6 patients), cardiac failure and portal hypertension (2 patients), and cardiac failure associated with biliary necrosis and portal hypertension (1 patient) ( Table 3 ).
The 7 already genotyped patients of this HHT population all had the ALK-1 mutation; all were transplanted because of a severe cardiac failure. 24, 25 Eighteen of 22 (81%) documented patients had pulmonary artery hypertension, defined as mean pulmonary artery pressure above 25 
Pretransplant Interventions
Pre-LT procedures had a high complication rate. Seven patients had an intervention to the hepatic artery. Four embolizations of HA or one of its branches were complicated by liver necrosis and acute heart failure (1 patient), biliary ischemia with cholangitis (1 patient), and abscess (1 patient). One right HA embolization successfully halted massive hemobilia. Two banding and embolization procedures of the common HA were complicated by biliary tree ischemia, acute heart, and renal failure in 1 case and by biliary sepsis in the other. One HA ligation caused liver necrosis with abscess. One patient had a resection of a pancreatoduodenal artery aneurysm.
Right facial (1 patient) and brachial artery (1 patient) embolizations were successful. Pulmonary AVMs were treated using embolization of left lower lobe AV fistula (1 patient), right upper lobectomy (1 patient), right lobectomy (1 patient), and unspecified pulmonary surgery (1 patient). This latter patient also had cholecystectomy and multiple surgical and radiologic liver abscess drainages. Hepatobiliary interventions in 6 other patients consisted of cholecystectomy and abscess drainage (1 patient), endoscopic sphincterotomy, cholecystectomy, and multiple abscess drainages (1 patient), abscess drainage (1 patient), liver resection for hemangioma (1 patient), laparoscopic cholecystectomy (1 patient), and even TIPSS procedure (1 patient).
Outcome After Transplantation
Classic LT was done in 48% of patients, the other patients had a caval preserving implantation technique. Venovenous bypass was used in 48% of transplant procedures. Median operating time was 439 minutes (range, 225-1071 minutes). Median cold and warm ischemia times were 561 minutes (range, 170 -935 minutes) and 55 minutes (range, 36 -80 minutes), respectively. LT seemed to be technically more demanding in HHT as exemplified by high blood product transfusion requirements (red blood cells: 4821 mL; range, 0 -23,657 mL; platelet requirement: 254 mL; range, 0 -4000 mL; and fresh frozen plasma: 4430 mL; range, 0 -28,000 mL) and prolonged hospital stay (intensive care stay: 9 days; range, 2-50 days; total stay: 28 days; range, 13-75 days). Pretransplant interventions, center experience, and era of transplantation did not have a negative impact on the transplantation procedure itself or outcome after LT.
Additional surgery was necessary in 6 of 35 documented patients and consisted of splenectomy (2 patients), resection of proper HA aneurysm (1 patient), ligation of splenic artery (1 patient), inferior vena cava thrombectomy (1 patient), and bleeding (1 patient). Actuarial 1-, 5-, and 10-year patient and graft survival rates are 82.5% ( Fig. 3) .
Seven (17.5%) patients died during or very early after LT from intraoperative bleeding (1 patient), acute rejection, and uncontrollable bleeding at re-LT (1 patient), acute heart failure at day 2 (1 patient), primary nonfunction at day 4 (1 patient), cerebral bleeding of ill-defined etiology at day 4 (1 patient), pulmonary bleeding due to ruptured AVM at day 6 (1 patient), and massive gastric bleeding due to ruptured AVM at day 12 (1 patient). One patient died after 127 months due to chronic rejection caused by noncompliance to immunosuppressive treatment.
Cardiovascular function, determined by echocardiography and/or right heart catheterization, improved after LT in 18 (75%) of 24 documented patients and remained stable in 5 others. 7, 8, 12, 16 One patient died, as mentioned, of acute heart failure at day 2. 8 Twenty-four (60%) patients had complications related to the transplant procedure. All but one of these complications occurred within the first 4 post-LT months. The surgical complications were as follows: primary nonfunction (2 patients), bleeding (9 patients), biliary complication (5 patients), abdominal collection (4 patients), hepatic artery thrombosis and pseudo-aneurysm (1 patient each), splanchnic vein thrombosis (1 patient), and jugular and subclavian vein thrombosis (1 patient). The medical complications were as follows: renal (6 patients) and respiratory (2 patients) failure; cholangitis (2 patients); upper airway bleeding (1 patient) and severe infection (13 patients). One patient had severe depression and chronic rejection due to noncompliance 96 months post-LT.
Acute rejection occurred in 18 (49%) of 37 documented patients. Eleven rejection episodes were corticosteroid-sensitive; 2 required OKT3 therapy. Chronic rejection was diagnosed 3 times; one rejection diagnosed at day 120 was reversed after increase of tacrolimus dosage.
Mean Karnofsky score, evaluated in 37 patients before and after LT, significantly improved from a pre-LT mean value of 56 (range, 20 -100; median, 55) to 97 (range, 80 -100; median, 100) in the post-LT setting.
Histologic Examination of the Hepatectomy Specimen
Median weight of the hepatectomy specimen was 1520 g (range, 495-4970 g; mean, 1769 g). Gross appearance showed, apart from the typical vascular malformations, very variable appearances (Table 4 ). Patients with cholangitis had features of diffuse intrahepatic biliary sludge and/or stones, cystic bile duct dilatation, bile-stained necrotic areas, and biliary mucosal necrosis.
Disease Recurrence
Two first cousin females, transplanted for mixed cardiac and biliary HHT disease, presented with focal vascular dilatations throughout the allograft at 156 and 84 months post-LT. 7, 22 Both had normal liver values. The first patient had anemia, nose bleeds, and melena due to gastric telangi-ectasia, while the second presented with a pulmonary AVM (Fig. 4 ). The first patient had angiography in the context of the GI bleed; in the second asymptomatic patient, angiography was performed in view of the cousin's history. As no biopsy was available, the differential diagnosis between intrahepatic recurrence of AVM or peliosis remains speculative. The similar findings in these 2 patients argue however more in favor of allograft disease recurrence. 
DISCUSSION
HHT or Rendu-Osler-Weber disease is a rare, autosomal dominant disease, which has an incidence of 1 to 2/100,000, a prevalence of 1 to 2/10,000 and a clinical penetrance of 97%. 26 The highest prevalence is recorded in Europe, with the greatest occurrence in the Danish island of Fyn and in the French departments of Ain, Jura, and Deux-Sèvres. 27 The disease is primarily described in whites but is also known among Asians, Arabs, and Africans. 3 At present, the diagnosis of HHT can be confirmed genetically. The genetic defect involves 2 major genes: ENG, encoding on chromosome 9, for endoglin, an accessory TGF-␤ receptor and ALK-1, encoding on chromosome 12, for activin receptor-like kinase type 1, a TGF-␤ type 1 receptor. 28 Both proteins are highly expressed on endothelial cells, explaining their important role in tissue repair and angiogenesis through their common function as receptors for TGF-␤. 1, 4 Specific genetic testing is very useful not only to confirm the diagnosis or to identify the responsible mutations in members of HHT families once the index family member has been identified but, probably more importantly, to explain the different clinical (phenotypic) manifestations of the disease and maybe to better indicate in which patients LT should be considered earlier. 1 Genetic heterogeneity underlies the clinical heterogeneity of this disease and the homozygous state is probably lethal. 3 HHT 1 families seem to have a higher prevalence of pulmonary AVMs, and HHT 2 families seem to have a milder and later onset but a higher incidence of liver involvement. 29, 30 This correlation between genotypes and phenotypes deserves further investigation. 31 It should be stressed in this context that the 7 genotyped patients of the ELTR-population had a ALK-1 defect leading to severe cardiac failure.
The typical lesions of HHT are focal, small dilatations of postcapillary venules that arise mainly in skin and mucosa but that can also be present in brain, lungs, digestive tract, and theoretically in every organ. [2] [3] [4] [5] [6] [7] Macroscopic telangiectasia may lead to arteriovenous malformation.
Liver involvement, classically reported in 8% to 31% of patients, has been shown to be present in up to 73% of patients using refined imaging. 11, 22, 32, 33 Fortunately, most HHT patients are asymptomatic and less than 5% to 15% of cases are referred with symptoms. Echo-color-Doppler ultrasound, multislice CT scan, and magnetic resonance imaging are all accurate noninvasive procedures to detect the liver involvement. This involvement occasionally is accompanied by a typical histologic pattern called pseudo-cirrhosis, which can develop silently and predominantly results in shunting from the hepatic artery to the hepatic vein (type 1, arterovenous shunt) and from the hepatic artery to the portal vein (type 2, arteroportal shunt). Portal to hepatic vein shunting (type 3, portovenous shunt) has more rarely been reported because it is more difficult to identify by CT scan. 10, 34, 35 Pathophysiology and clinical presentation of HHT depend on the type and size of the shunt. A type 1 shunt is responsible for "stealing" blood from the arterial to the venous stream with development of a hyperdynamic circulation leading to high-output right cardiac failure and to ischemia of the biliary tree with risk of cholangitis, necrosis, and sepsis. The rarer type 2 shunt can induce portal hypertension, especially when the AV fistula, which mainly arises from an aneurysm, is large. 5 This hypertensive state can be further worsened by the remodeling of the liver parenchyma in the form of pseudocirrhosis due to ischemia-induced regenerative nodular-like formation and by the development of heart failure. 36 Focal nodular hyperplasia is the most frequent type of liver parenchymal remodeling, and its frequency (up to 24% of cases) is higher in case of severe hepatic involvement. 37 Type 3 is currently detectable by histologic, angiographic, and/or corrosion cast studies only. 5 Factors determining the relatively higher prevalence of one or another type of shunt formation are unknown but may be related to the genetic background. 29, 30 According to shunt type and size, Garcia-Tsao has classified patients into 3 groups presenting with cardiac failure, biliary disease, or portal hypertension 2,5,10 -12 ( Table  1 ). The clinical manifestations of hepatic involvement may overlap and fluctuate over time, sometimes even showing partial spontaneous remissions. Type 1 shunt can cause a cardiac and/or biliary-type clinical pattern. Cholestasis is the most frequent biochemical marker, indicating bile duct ischemia, even when the clinical evolution is dominated by cardiovascular signs. Cardiac output is nearly always increased in HHT patients. 11 Cardiovascular symptoms are present when intrahepatic shunt output is more than 20% of cardiac output. 5, 8, 36, 37 Shunt output has been reported as high as 68% of cardiac output. 39 Type 2 shunts may cause major portal hypertension, whereas the clinical impact of type 3 shunts has not been well defined yet.
Until recently, conservative management has been used for first-line treatment; however, the goal of HHT therapy should be to eliminate the AVM or TA. 2,5,8,11,12,14 -16 The treatment of hepatic-based HHT has never been clearly established. From this survey, it becomes clear that interventions to the hepatic arterial bed are hazardous and dangerous. Ligation, banding, and embolization of the hepatic artery should not be performed in view of the high risk of biliary necrosis and sepsis with a 20% mortality risk. These procedures, moreover, may damage the liver vascularization, thereby provoking the development of new shunts. 12,14 -16,38 Interventions on the hepatic artery are particularly hazardous when both hepatic artery-hepatic vein and portal vein-hepatic vein shunts are present. Indeed, in such cases, the interruption of the arterial blood supply leaves the hepatic blood flow trough the portal vein only, which on its turn is also shunted. Screening for venovenous shunting using Doppler (color) ultrasound or high-volume arterial portography could increase the safety of such interventions. 40 In well-selected patients, arterial embolization can have a lasting clinical effect, even up to 50 months, due to the significant decrease of cardiac output immediately after the procedure. 14 The first case of LT for HHT was performed by the Hannover group in 1985. This index patient is still alive and in good condition. Unfortunately, the 2 subsequent patients, transplanted in 1987 and 1989, died after LT due to intraoperative bleeding and primary graft nonfunction, indicating the technical difficulties of transplant surgery. The first case of LT for HHT reported in the English literature was published 10 years later, 7 followed by a few anecdotal reports. 8, 11, 13, [15] [16] [17] [18] [19] [20] The largest series, comprising 6 cases, was reported in 2002. 12 The world experience now comprises 44 cases, 4 of whom were transplanted in the United States and the remaining 40 cases form the basis of this report 9,21 ( Fig. 1 ; Table 3 ). This ELTR survey is the first study focusing on the role of LT in the treatment of this rare vascular disorder. The results indicate that LT represents a valuable, and most of all definitive, therapy in case of hepatic HHT leading to major cardiac failure and/or liver failure and/or massive biliary necrosis and/or development of major portal hypertension. The excellent survival rates compare favorably to the overall survival in the whole ELTR. 41 Timing of LT is essential, especially in the setting of biliary infection with sepsis and major cardiac failure. LT should also be considered in cases of secondary pulmonary arterial hypertension before fixed hypertension occurs. Patients should thus be referred early to a specialized center, especially if ascites, the commonest clinical expression of irreversible liver and/or heart failure, and if cholestasis and/or biliary sepsis are present. Severe cholestasis is correlated with the disease severity. 42 The necessity for timely transplantation is very well exemplified by the recent reporting from Yale. Indeed, 17 of 51 HHT patients presenting hepatic involvement died after a mean follow-up of 4.8 years. One patient died after LT; 14 (28%) of the remaining 50 patients died as a direct consequence of cardiopulmonary or biliary disease. 43 Early LT permits complete recovery from these potentially lethal conditions by removing the source of the ongoing (biliary) sepsis and cardiopulmonary and/or liver failure. 16, 19 In view of the high incidence of pulmonary hypertension, complete pretransplant invasive, cardiopulmonary investigation is necessary. The Berlin, Paris, Cambridge, Lyon, and Besançon groups provided evidence that right heart function, pulmonary pressure, cardiac output, and clinical symptoms normalize after LT in all studied patients 7, 8, 12, 16, 25 (Table 3 ). These findings are in line with the reversibility of cardiopulmonary function after treatment of splanchnic AVMs. 40, 44 Treatment of major pulmonary, and probably of other, AVMs should be considered before LT, as this condition can lead to severe, even lethal, post-LT bleeding, as shown in these ELTR series. The value of LT in symptomatic HHT is moreover exemplified by the dramatic improvement of Karnofsky scores, a very reliable and easy parameter to judge quality of life in transplant patient. These excellent results can be obtained despite the enhanced surgical difficulties, reflected by greater transfusion need, long operating time, prolonged hospital stay, and a high postoperative morbidity and mortality related to heart failure and bleeding.
The possible rare allograft recurrence recently described in 2 female first-degree cousins (included in this ELTR series) remains intriguing. 22 The first patient experienced melena due to gastric TA, justifying angiography, which surprisingly revealed a focal hepatic AVM. In view of these findings, her asymptomatic cousin had a CT scan and angiography, which also revealed diffuse allograft vascular dilatations. Their suspected AVM allograft recurrence is important because they may provide further insight into the understanding of the pathophysiology of HHT. It still remains possible that these angiographic findings are compatible with the diagnosis of peliosis hepatis. These 2 cases indicate that careful long-term follow-up is mandatory and that genetic screening is desirable in these patients. Similar findings in other transplanted organs in HHT patients could provide more insight regarding the problem of disease recurrence. Unfortunately, such data are not available at present as only 2 cases of lung transplantation have been reported thus far. One patient died and no detailed follow-up is available for the other. 45, 46 This ELTR survey, which includes 40 patients, is the first large study to focus on the role of LT in the treatment of this rare vascular hepatic disorder. A systematic registration of all vascular liver-based disorders, including genetic counseling, would be the only way to further improve the outcome of symptomatic HHT patients. Indeed, we, as others, experienced some fatal outcomes of these patients from cardiac or infectious problems while being considered for or while awaiting transplantation during the studied period. our patients, sildenafil, which is excellent in decreasing the pulmonary hypertension? DR. JAN LERUT: Thank you. First in relation to histology, what I mentioned in the paper is that several patients had liver biopsy before transplantation because the diagnosis was not known in about one fourth of patients. It is one of the points I wanted to stress in this work that this disease is largely underestimated. Since we completed the study, we now receive regular phone calls about what to do with patients who seem to have Rendu-Osler-Weber disease in the liver.
The second thing regarding biliary necrosis: you can have severe septic biliary sepsis related to necrosis but the necrosis is not always diffusely involving the liver. I think that if you have extensive necrotic areas like you have seen in this liver, these patients should not be treated by means of hepatic resection because it is too dangerous and, of course, the disease is sitting everywhere in the liver. Therefore, we must be more radical. The more interventions you do, the worse the outlook. We have seen several patients undergoing classic surgical treatment or interventional endoscopy for biliary complications, but I would say, as for cystic biliary disease and Caroli disease, you will enhance further the septic risk to you patient and compromise the results of transplantation.
All the patients, of course, did not get cerebral imaging. I think the simplest one is to have magnetic nuclear resonance in the pretransplant workup. This is fundamental, and as you have seen, 1 patient died despite successful transplantation because of cerebral hemorrhage. In relation to the pulmonary hypertension, though, I think we had 22 patients with complete documentation pre-and post-transplantation. If you find elevated pulmonary pressures in the context of arteriovenous malformation, I think these patients should not be considered with other cirrhotic patients with pulmonary hypertension. It is a completely different story. We know, for arteriovenous malformations in the splanchnic territory, that if you interrupt them, you can reduce pulmonary hypertension and portal hypertension. It is just a mechanical phenomenon that will reverse, on the condition that you don't leave your patient with pulmonary hypertension for 10, 15, or 20 years. The value of early intervention has been well documented, and we even published it in Gastroenterology many years ago.
DR. HENRI BISMUTH: Jan, how do you explain the recurrence of a genetic disease on the liver graft? DR. JAN LERUT: This was, of course, a surprise for us because these were the only 2 patients in whom we did not have follow-up more than 5 years after transplantation. Through different channels, we traced back the patients. We knew the history of 1 patient-he underwent angiography because of GI bleeding-you have seen this. He had a family member who was transplanted in another hospital far away, but no doctor knew that these patients were related. Angiog-raphy was done and showed the same findings. Now, if we want to know whether this is recurrent disease really, it is not so easy. It could have been related to peliosis of the liver but, in my experience, the patients did not have azathioprine or other medication which might have resulted in peliosis. In my experience, if you undertake nuclear magnetic resonance imaging for this condition, you don't have a picture like this. We can only understand if the disease recurs if we go to other fields of transplantation and, indeed, there have been only 2 patients transplanted for lung disease. Unfortunately, 1 patient died immediately after the operation, and in the second case, the report in the literature gives only a follow-up of 6 months. It would be interesting to see if the disease recurs in another setting of transplantation, but there is still no explanation yet for this. There is a plan to look at stem cell research and also undertake detailed genetic examination of these patients.
DR. JAMES GARDEN: I very much enjoyed this paper. I think it shows wonderfully well how pulling the experience together can lead to further improvements in the assessment and management of these patients. What I was a bit surprised about in your paper was that it seemed that there were very few patients who ran into problems as a consequence of the preexisting cardiac failure. I wonder, just for those centers that might stumble across this condition in the future, are there particular tricks or recommendations that can be made on the basis of this experience that would ensure that patients don't come to grief because of cardiac problems? DR. JAN LERUT: Thank you for this very good question. I think, if the patient has severe cardiac disease, the only trick is to list him as soon as possible for transplantation. We lost 2 patients on the waiting list because of cardiac disease. When you list them in the system, they cannot go up in the list; and now we are making in Europe transplants as also for UNOS that these patients will go into a particular group. You can document with numbers exactly what the cardiopulmonary status is, so that you do not cheat in putting your patient in the front of the list.
Just to give an additional comment, in the United States, it is said that this disease is not a validated indication for transplantation. The center in Yale has collected more than 1000 patients with this disease, of whom 51 patients had severe hepatic disease. Although this center claimed that you almost never need aggressive therapy, already 17 of these 51 patients had died; only 1 was transplanted (he died after transplantation), and 1 is, I believe, waiting for transplantation. So, for me, the conclusion is very clear in this study. Severe complication is equal to rapid transplantation. DR. TONI LERUT: You showed a nice illustration of an arteriovenous pulmonary malformation, and we know that patients die of such pulmonary malformations. I just wonder whether you know what sort of treatment they had as otherwise they continue to be at risk for cardiac decompensation. Eventually, in particular in case of diffuse malformation, are they potential candidates for pulmonary transplantation?
DR. JAN LERUT: Good question, of course! So, this gives me the opportunity to see my brother! So, what we do is, we do a complete screening of the lung. We favor interventional radiology. It's easy to block the fistula and further assess the presence of diffuse disease in the lung. So, what we know out of the registry is that 3 patients had pulmonary resection-not a complete but a segmental resection and 1 patient had interventional radiologic treatment-you have seen on the pictures, at the right and left side. Usually, the arteriovenous malformation is in the lower lobes; it's easily accessible for the interventional radiologist.
